权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease

β-地中海贫血和镰状细胞病的体内造血干细胞基因治疗

基本信息

批准号：
10685978
负责人：
ANDRE Michael LIEBER
金额：
$ 65.79万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10685978
关键词：
Adenoviruses Aftercare Ambulatory Care Blood Cells Bone Marrow Bone Marrow Aspiration Bone Marrow Purging CD46 Antigen CRISPR/Cas technology Capsid Carmustine Cell Transplantation Cells Clinical Communicable Diseases Data Defect Developing Countries Disease model Dose Engineering Erythrocytes Erythroid Cells Erythropoietin Erythropoietin Receptor Evaluation Fetal Hemoglobin Gene Transfer Genes Genetic Globin Goals Harvest Hematological Disease Hematopoietic Stem Cell Mobilization Hematopoietic stem cells Hemoglobinopathies Hemophilia A High Dose Chemotherapy Human IL1R1 gene Immunity Immunologic Deficiency Syndromes Immunotherapy In Vitro Injections Intravenous Knock-out Leukapheresis Macaca mulatta Mediating Methods Modification Mus Mutation Outcome Patients Peripheral Phenotype Price Primates Procedures Process Proliferating Prophylactic treatment Protocols documentation Regimen Risk Safety Series Sickle Cell Anemia Sleeping Beauty Stem cell pluripotency Steroids System Technology Testing Thalassemia Toxic effect Toxicology Transgenes Transgenic Mice Transposase Viral Vector Virus antagonist beta Thalassemia cellular transduction cesium chloride chemotherapy clinical application cost cost effectiveness curative treatments cytokine design driving force efficacy study fetal reactivity gene therapy gene transfer vector genome editing gutless adenoviral vector humanized mouse improved in vivo intravenous injection mouse model nonhuman primate patient population pharmacologic portability pre-clinical preclinical study preference prevent repaired response side effect stem cell gene therapy stem cell genes thalassemia intermedia therapeutic transgene trait transgene expression vector

项目摘要

Abstract: Hematopoietic stem cell (HSC) gene therapy could provide a curative treatment for a number of blood diseases. The conventional approach is based on ex vivo HSC gene transfer and has achieved encouraging results. However, the high cost and side effects limit the patient accessibility of ex vivo HSC gene therapy. We have developed an in vivo HSC transduction approach involving HSC mobilization and intravenous viral vector injection. The approach is highlighted by its relatively low cost and technical simplicity. It could be provided as an outpatient treatment. We have demonstrated its safety and efficacy in several murine disease models, including β-thalassemia, Sickle Cell Anemia, and hemophilia A, and more recently, in rhesus macaques. With more gene therapy products on the horizon, the application of in vivo HSC transduction could extrapolate genetic treatments to a larger patient population. Further improvements of in vivo HSC gene therapy on the road to clinical application include more effective mobilization protocols, complete elimination of innate responses upon intravenous vector injection, more advanced virus capsid modifications that circumvent pre-existing anti-vector immunity, improved in vivo selection regimens, as well as new methods for purification of gene transfer vectors. In this application, we will successively test hypotheses to improve in vivo HSC gene therapy approaches for thalassemia and Sickle Cell Disease in mouse models. We will then validate the best combination of improvements in hon-human primates. Safety, efficacy, portability, and low costs are the major driving forces in the design/optimization of each technological unit.

摘要：造血干细胞（HSC）基因治疗可以为许多血液病提供治愈性治疗。传统的方法是基于离体HSC基因转移，并取得了令人鼓舞的结果。然而，高成本和副作用限制了离体HSC基因治疗的患者可及性。我们有开发了一种涉及HSC动员和静脉内病毒载体的体内HSC转导方法注射该方法的特点是成本相对较低，技术简单。它可以被提供为门诊治疗我们已经在几种鼠疾病模型中证明了其安全性和有效性，包括β-地中海贫血、镰状细胞贫血和血友病A，以及最近在恒河猴中的研究。与随着越来越多的基因治疗产品的出现，体内HSC转导的应用可以外推基因治疗，为更多的患者群体提供治疗。进一步改进体内HSC基因治疗，临床应用包括更有效的动员方案，完全消除先天性反应，静脉内载体注射，更先进的病毒衣壳修饰，其避开预先存在的抗载体免疫力、改进的体内选择方案以及用于纯化基因转移载体的新方法。在本申请中，我们将连续测试假设，以改善体内HSC基因治疗方法，地中海贫血和镰状细胞病小鼠模型。然后，我们将验证以下各项的最佳组合在非人类灵长类动物身上的进步安全性、有效性、便携性和低成本是每个技术单元的设计/优化。

项目成果

期刊论文数量（16）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

In vivo HSC prime editing rescues sickle cell disease in a mouse model.

体内 HSC Prime 编辑可挽救小鼠模型中的镰状细胞病。

DOI：
10.1182/blood.2022018252
发表时间：
2023-04-27
期刊：
BLOOD
影响因子：
20.3
作者：
Li, Chang;Georgakopoulou, Aphrodite;Newby, Gregory A.;Chen, Peter J.;Everette, Kelcee A.;Paschoudi, Kiriaki;Vlachaki, Efthymia;Gil, Sucheol;Anderson, Anna K.;Koob, Theodore;Huang, Lishan;Wang, Hongjie;Kiem, Hans-Peter;Liu, David R.;Yannaki, Evangelia;Lieber, Andre
通讯作者：
Lieber, Andre

In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor.

DOI：
10.1089/hum.2021.295
发表时间：
2022-04
期刊：
HUMAN GENE THERAPY
影响因子：
4.2
作者：
Wang, Hongjie;Li, Chang;Obadan, Adebimpe O.;Frizzell, Hannah;Hsiang, Tien-Ying;Gil, Sucheol;Germond, Audrey;Fountain, Connie;Baldessari, Audrey;Roffler, Steve;Kiem, Hans-Peter;Fuller, Deborah H.;Lieber, Andre
通讯作者：
Lieber, Andre

In Vivo Hematopoietic Stem Cell Transduction.

DOI：
10.1016/j.hoc.2017.06.001
发表时间：
2017-10
期刊：
Hematology/oncology clinics of North America
影响因子：
0
作者：
Richter M;Stone D;Miao C;Humbert O;Kiem HP;Papayannopoulou T;Lieber A
通讯作者：
Lieber A

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements.

使用大调控元件对小鼠地中海贫血进行体内造血干细胞基因治疗。

DOI：
10.1172/jci.insight.139538
发表时间：
2020
期刊：
JCI insight
影响因子：
8
作者：
Wang,Hongjie;Georgakopoulou,Aphrodite;Li,Chang;Liu,Zhinan;Gil,Sucheol;Bashyam,Ashvin;Yannaki,Evangelia;Anagnostopoulos,Achilles;Pande,Amit;Izsvák,Zsuzsanna;Papayannopoulou,Thalia;Lieber,André
通讯作者：
Lieber,André

Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies.

DOI：
10.1016/j.omtm.2018.02.004
发表时间：
2018-06-15
期刊：
Molecular therapy. Methods & clinical development
影响因子：
0
作者：
Li C;Psatha N;Wang H;Singh M;Samal HB;Zhang W;Ehrhardt A;Izsvák Z;Papayannopoulou T;Lieber A
通讯作者：
Lieber A